United States — Food and Drug Administration & Abbott Laboratories

United States — Food and Drug Administration: The United States — Food and Drug Administration's rule allowing mifepristone to be prescribed online and dispensed through the mail was temporarily halted by an appellate court, but later paused by the United States — Supreme Court of the United States. The agency is conducting a safety review of mifepristone.

Abbott Laboratories: Abbott Laboratories, the maker of mifepristone, received temporary relief from Samuel Alito's order, allowing continued mail access to the drug. The company appealed to the United States — Supreme Court of the United States to set aside the appellate court's order and expressed concern about the 'immediate confusion and upheaval' caused by the 5th Circuit's decision.

United States — Food and Drug Administration: The United States — Food and Drug Administration's regulations allowing mail-order mifepristone were overruled by the United States — United States Court of Appeals for the Third Circuit, despite the agency's long-standing judgments on drug safety.

Abbott Laboratories: Abbott Laboratories, a manufacturer of Mifepristone, is a defendant in the lawsuit and has requested a hold on the appeals court's order to seek relief from the United States — Supreme Court of the United States.

United States — Food and Drug Administration: The United States — Food and Drug Administration's regulations regarding mifepristone access were challenged, and the agency is conducting a safety review of the medication.

Abbott Laboratories: Abbott Laboratories, the maker of mifepristone, filed an emergency appeal to the United States — Supreme Court of the United States, which led to the temporary restoration of access to the drug.

United States — Food and Drug Administration: The United States — Food and Drug Administration is experiencing a leadership change with the resignation of its Commissioner, Marty Makary, and the appointment of Kyle Diamantas as acting chief. The agency has faced internal clashes, policy confusion, and criticism during Marty Makary's tenure.

Abbott Laboratories: Abbott Laboratories is a company whose fruit-flavored e-cigarettes were approved by the United States — Food and Drug Administration after Donald Trump reportedly pushed Marty Makary to accelerate the approval process.

Abbott Laboratories: Abbott Laboratories is mentioned in the context of a previous infant formula recall in 2022, which caused a national shortage, providing a comparison point for the current ByHeart recall.

Abbott Laboratories: Abbott Laboratories, through its Abbott Diabetes Care division, is at the center of this event due to the recall of its FreeStyle Libre 3 and FreeStyle Libre 3 Plus glucose monitor sensors. The malfunction has led to serious injuries and deaths, negatively impacting the company's reputation and potentially its stock price.